Last: | $1.44 |
---|---|
Change Percent: | 0.0% |
Open: | $1.41 |
Close: | $1.44 |
High: | $1.5201 |
Low: | $1.3875 |
Volume: | 144,157 |
Last Trade Date Time: | 07/23/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$1.44 | $1.41 | $1.44 | $1.5201 | $1.3875 | 144,157 | 07-23-2024 |
$1.41 | $1.31 | $1.41 | $1.4454 | $1.26 | 243,949 | 07-22-2024 |
$1.32 | $1.35 | $1.32 | $1.39 | $1.32 | 84,563 | 07-19-2024 |
$1.38 | $1.41 | $1.38 | $1.525 | $1.365 | 169,692 | 07-18-2024 |
$1.43 | $1.47 | $1.43 | $1.49 | $1.405 | 144,843 | 07-17-2024 |
$1.5 | $1.3 | $1.5 | $1.59 | $1.3 | 719,828 | 07-16-2024 |
$1.31 | $1.27 | $1.31 | $1.34 | $1.26 | 190,194 | 07-15-2024 |
$1.28 | $1.26 | $1.28 | $1.28 | $1.25 | 149,930 | 07-12-2024 |
$1.24 | $1.21 | $1.24 | $1.2601 | $1.205 | 279,671 | 07-11-2024 |
$1.18 | $1.21 | $1.18 | $1.22 | $1.16 | 103,219 | 07-10-2024 |
$1.22 | $1.25 | $1.22 | $1.25 | $1.21 | 157,090 | 07-09-2024 |
$1.23 | $1.23 | $1.23 | $1.28 | $1.14 | 390,794 | 07-08-2024 |
$1.21 | $1.1 | $1.21 | $1.24 | $1.09 | 385,414 | 07-05-2024 |
$1.1 | $1.12 | $1.1 | $1.13 | $1.09 | 55,746 | 07-04-2024 |
$1.1 | $1.12 | $1.1 | $1.13 | $1.09 | 55,746 | 07-03-2024 |
$1.09 | $1.13 | $1.09 | $1.14 | $1.08 | 214,333 | 07-02-2024 |
$1.13 | $1.17 | $1.13 | $1.1802 | $1.08 | 364,978 | 07-01-2024 |
$1.16 | $1.2 | $1.16 | $1.2 | $1.12 | 225,823 | 06-28-2024 |
$1.18 | $1.19 | $1.18 | $1.22 | $1.14 | 155,072 | 06-27-2024 |
$1.16 | $1.24 | $1.16 | $1.24 | $1.14 | 231,129 | 06-26-2024 |
News, Short Squeeze, Breakout and More Instantly...
CEL-SCI Corporation (NYSE American: CVM) today announced that Robert (“Bob”) Watson, who has served as a Director of the Company since 2017, has been appointed Chairperson of the Board. Bob is an accomplished business leader who began his career as an investment banker. Wi...
Multikine significantly increases overall survival in patients with low levels of tumor cell PD-L1 expression in contrast to approved checkpoint inhibitors 73% survival for Multikine vs 45% in the control arm at 5 years Statistically significant log rank p = 0.0015 ...
Dr. Selvaggi was instrumental in the development and approval of lung cancer drugs Zykadia for Novartis and Opdivo for Bristol Myers Squibb CEL-SCI’s Multikine immunotherapy improves the 5-year survival of head and neck cancer patients to 73% compared to 45% in controls and cut...